Skip to content
DataLookout
Menu

RepAIR1NCT07431112

A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 24, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 12 → 15 locations
  2. Notable Eligibility criteria expanded, about 40 words
    • Trial sites expanded: 8 → 12 locations
  3. Minor Study sites: 6 to 8v7
  4. Minor Study sites: 4 to 6v6
  5. Minor Study sites: 3 to 4v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Start date: Feb 27, 2026 to Mar 17, 2026v4
  2. Minor Study sites: 2 to 3v3
  3. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Eligibility criteria shortened, about 51 words
    • Primary endpoints: 1 to 4
    • Study sites: 1 to 2
    • Start date changed from estimate of Feb 2026 to Feb 27, 2026
    • Secondary endpoints revised (3)
    • Study title shortened, about 2 words
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with treatment-emergent adverse events (TEAEs)
Timeframe: Up to Day 169
Incidence of laboratory abnormalities and shifts from baseline, including hematology, chemistry, coagulation, and urinalysis parameters
Timeframe: Baseline through up to Day 169
Incidence of abnormal vital signs
Timeframe: Baseline through up to Day 169
Incidence of abnormal electrocardiogram (ECG) findings
Timeframe: Baseline through up to Day 169

Secondary (3)

Area under the plasma concentration time curve for AIR-001 from time of dosing to the last measurable concentration (AUClast)
Maximum concentration of AIR-001 in plasma (Cmax)
Change from baseline in levels of total serum AAT protein, including serum M-AAT, Z-AAT, and functional AAT protein

Arms and interventions

AIR-001 SAD Cohort 1Experimental

AIR-001 is an RNA-editing oligonucleotide in sterile preservative-free solution administered by subcutaneous (SC) injection as a single dose.

AIR-001 SAD Cohort 2Experimental

AIR-001 administered by SC injection as a single dose.

AIR-001 SAD Cohort 3Experimental

AIR-001 administered by SC injection as a single dose.

AIR-001 SAD Cohort 4Experimental

AIR-001 administered by SC injection, single dose.

AIR-001 MD Cohort 1Experimental

AIR-001 is an RNA-editing oligonucleotide in sterile preservative-free solution administered by subcutaneous (SC) injection as multiple doses.

AIR-001 MD Cohort 2Experimental

AIR-001 administered by SC injection as multiple doses.

AIR-001 MD Cohort 3Experimental

AIR-001 administered by SC injection as multiple doses.

AIR-001 MD Cohort 4Experimental

AIR-001 administered by SC injection as multiple doses.

AIR-001 MD Cohort 5Experimental

AIR-001 administered by SC injection as multiple doses.

AIR-001 MD Cohort 6Experimental

AIR-001 administered by SC injection as multiple doses.

Drugs: AIR-001 SAD dose level 1, AIR-001 SAD dose level 2, AIR-001 SAD dose level 3, AIR-001 SAD dose level 4, AIR-001 MD dose level 1, AIR-001 MD dose level 2, AIR-001 MD dose level 3, AIR-001 MD dose level 4, AIR-001 MD dose level 5, AIR-001 MD dose level 6

Sites

15 sites in 9 countries

United Kingdom 4, Germany 3, Georgia 2, Australia 1, Netherlands 1, New Zealand 1, Portugal 1, Spain 1, Sweden 1